TC BioPharm Current Valuation vs. Current Ratio

TCBP Stock  USD 0.58  0.05  7.94%   
Taking into consideration TC BioPharm's profitability measurements, TC BioPharm Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess TC BioPharm's ability to earn profits and add value for shareholders. As of 12/12/2024, Price To Sales Ratio is likely to drop to 0.62. In addition to that, Days Sales Outstanding is likely to drop to 9.18. At this time, TC BioPharm's Total Other Income Expense Net is relatively stable compared to the past year. As of 12/12/2024, Income Quality is likely to grow to 2.50, while Interest Income is likely to drop 1,888.
For TC BioPharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of TC BioPharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well TC BioPharm Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between TC BioPharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of TC BioPharm Holdings over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TC BioPharm. If investors know TCBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TC BioPharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.87)
Earnings Share
(192.95)
Revenue Per Share
29.639
Quarterly Revenue Growth
1.886
Return On Assets
(1.09)
The market value of TC BioPharm Holdings is measured differently than its book value, which is the value of TCBP that is recorded on the company's balance sheet. Investors also form their own opinion of TC BioPharm's value that differs from its market value or its book value, called intrinsic value, which is TC BioPharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TC BioPharm's market value can be influenced by many factors that don't directly affect TC BioPharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TC BioPharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if TC BioPharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TC BioPharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

TC BioPharm Holdings Current Ratio vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining TC BioPharm's current stock value. Our valuation model uses many indicators to compare TC BioPharm value to that of its competitors to determine the firm's financial worth.
TC BioPharm Holdings is rated below average in current valuation category among its peers. It is rated below average in current ratio category among its peers . The ratio of Current Valuation to Current Ratio for TC BioPharm Holdings is about  29,642,337 . At this time, TC BioPharm's Current Ratio is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value TC BioPharm by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

TCBP Current Valuation vs. Competition

TC BioPharm Holdings is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 285.33 Million. TC BioPharm claims roughly 5.63 Million in current valuation contributing just under 2% to equities under Health Care industry.

TCBP Current Ratio vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

TC BioPharm

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
5.63 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

TC BioPharm

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
0.19 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).

TCBP Current Ratio Comparison

TC BioPharm is currently under evaluation in current ratio category among its peers.

TC BioPharm Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in TC BioPharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, TC BioPharm will eventually generate negative long term returns. The profitability progress is the general direction of TC BioPharm's change in net profit over the period of time. It can combine multiple indicators of TC BioPharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income-83 K-87.2 K
Interest IncomeK1.9 K
Operating Income-14.2 M-15 M
Net Loss-5.9 M-6.2 M
Income Before Tax-7 M-7.3 M
Total Other Income Expense Net7.2 M7.6 M
Net Loss-1.6 M-1.7 M
Net Loss-5.9 M-6.2 M
Income Tax Expense-1.1 M-1 M
Change To Netincome-7.5 M-7.1 M
Net Loss(191.21)(200.77)
Income Quality 1.79  2.50 
Net Income Per E B T 0.84  0.86 

TCBP Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on TC BioPharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of TC BioPharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the TC BioPharm's important profitability drivers and their relationship over time.

Use TC BioPharm in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.

TC BioPharm Pair Trading

TC BioPharm Holdings Pair Trading Analysis

The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your TC BioPharm position

In addition to having TC BioPharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large & Mid Caps ETFs Thematic Idea Now

Large & Mid Caps ETFs
Large & Mid Caps ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large & Mid Caps ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large & Mid Caps ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for TCBP Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.